Neil's mailing address filed with the SEC is ONE KENDALL SQUARE, BUILDING 1400E, SUITE 14-105, CAMBRIDGE, MA, 02139.
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts.
Anchiano Therapeutics Ltd executives and other stock owners filed with the SEC include: